Cellectis S.A. is a clinical-stage biotechnology company based in Paris, France, specializing in immuno-oncology and gene-editing technologies. The company focuses on developing allogeneic Chimeric Antigen Receptor T-cell (UCART) therapies aimed at targeting and destroying cancer cells. Key product candidates include UCART19 for treating CD19-expressing hematologic malignancies, UCART123 for acute myeloid leukemia, and therapies for multiple myeloma such as UCARTCS1 and ALLO-715. In addition to its therapeutic segment, Cellectis operates a subsidiary, Cellectis Bioresearch SAS, which develops meganuclease-based products for creating stable cell lines and offers genome customization tools for drug discovery and protein production. The company has established strategic partnerships with various organizations, enhancing its research and development capabilities. Founded in 1999, Cellectis continues to advance its innovative approaches to cancer treatment.
Cellartis AB is a Swedish/British biotechnology company focused on pluripotent stem cells and technology for drug discovery research, toxicity testing and regenerative medicine Since 2001, Cellartis has worked globally with industry and academia, platform providers and end users to develop the next generation of advanced stem cell products and technologies. The company leverages a deep experience in stem cell handling, scale up and differentiation into mature and functional human cells. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools today.
Cyto Pulse Sciences
Acquisition in 2010
Cyto Pulse Sciences is a biomedical device and treatment development company. It develops electric field based devices for production of DNA therapeutic vaccines, delivery of DNA vaccines, modification of cell genomes to correct genetic defects, production of hybridoma cell vaccines by fusing immune system cells and tumor cells, and the production of hybridomas used to produce monoclonal antibodies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.